CDKN2B anticorps
Aperçu rapide pour CDKN2B anticorps (ABIN2718414)
Antigène
Voir toutes CDKN2B AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Attributs du produit
- Homo sapiens cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B), transcript variant 1
-
Purification
- Purified from mouse ascites fluids by affinity chromatography
-
Immunogène
- Full length human recombinant protein of human CDKN2B(NP_004927) produced in HEK293T cell.
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- WB 1:2000, FLOW 1:100,
-
Commentaires
-
The concentration of the product may vary between diferrent lots.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5-1.0 mg/mL
-
Buffer
- PBS (PH 7.3) containing 1 % BSA, 50 % glycerol and 0.02 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
-
- CDKN2B (Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B))
-
Autre désignation
- CDKN2B
-
Sujet
- This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.
-
Poids moléculaire
- 14.5 kDa
-
ID gène
- 1030
-
NCBI Accession
- NM_004936
-
HGNC
- 1030
-
Pathways
- Cycle Cellulaire, Mitotic G1-G1/S Phases
Antigène
-